The EIF3L Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the EIF3L gene in a widely used human cervical adenocarcinoma model. This product provides a loss-of-function resource for investigating the eIF3 complex and translation initiation mechanisms. The polyclonal knockout cells harbor a heterogeneous set of targeted gene disruptions generated by CRISPR/Cas9-mediated editing, enabling pooled analysis of EIF3L deficiency without selection for a single clonal genotype. This format is well-suited for transient or stable knockdown validation, high-content screening, and functional genomics experiments that prioritize population-level translation phenotypes over clonal homogeneity.
HeLa cells, the host line for this knockout product, are an epithelial cell line originally derived from an HPV18-positive cervical adenocarcinoma. Known for their robust growth characteristics and genetic tractability, HeLa cells have become a cornerstone of cancer cell biology, virology, and molecular pharmacology. The HPV18 integration drives constitutive expression of E6 and E7 oncoproteins, which partially disrupt p53 and Rb pathways, creating a background of heightened proliferative signaling and altered translational control. This context makes the HeLa line particularly relevant for dissecting how oncogenic stress interfaces with the translational machinery.
EIF3L encodes subunit L of the eukaryotic translation initiation factor 3 (eIF3) complex, a multi-protein assembly that orchestrates cap-dependent translation by bridging eIF4G-bound mRNA with the 40S ribosomal subunit. The eIF3 complex comprises at least 13 non-identical subunits (including EIF3A?CEIF3M) that serve scaffolding and regulatory roles. EIF3L specifically interacts with other core subunits such as EIF3A, EIF3B, EIF3C, EIF3D, EIF3E, EIF3F, EIF3H, EIF3I, EIF3K, and EIF3M, as well as with eIF4G to facilitate 40S recruitment. Upstream, translation initiation is tightly controlled by the mTOR signaling pathway: mTOR kinase directly or indirectly regulates 4E-BP1 phosphorylation, releasing eIF4E to engage eIF4G and the eIF4A helicase. EIF3L activity is therefore influenced by growth factor signaling, serum stimulation, and the MYC transcriptional program. Disruption of EIF3L impairs ribosomal scanning and global protein synthesis, thereby dampening downstream cap-dependent translation.
In the HeLa background, loss of EIF3L has significant implications for cancer cell biology. Given that cervical adenocarcinoma cells exhibit dysregulated mTOR signaling and elevated cap-dependent translation, the knockout model helps elucidate how individual eIF3 subunits contribute to oncogenic protein synthesis and ribosome recruitment. The interplay between EIF3L and other eIF3 components may modulate cellular responses to nutrient deprivation or mTOR inhibitors, offering a platform to study adaptive translation reprogramming. This model also allows examination of whether EIF3L depletion selectively affects mRNAs with specific 5?? untranslated region features, an area of active investigation in translation control.
Researchers can employ these polyclonal EIF3L knockout HeLa cells for a range of applications including functional dissection of the eIF3 complex, evaluation of translation initiation dynamics, and screening for small-molecule translation inhibitors. Representative assays include polysome profiling to assess ribosomal loading, puromycin incorporation assays to measure de novo protein synthesis, Western blotting for eIF3 subunit expression, RT-qPCR for target gene transcripts, and cell proliferation analyses via MTT or CCK-8 assays. RNA-seq can further reveal transcriptome-wide changes in translational efficiency. These applications support studies in cancer biology, signaling, and drug discovery. For further information or to discuss specific experimental needs, please contact Ascent Research.
